SCHEMBL1201165

SCHEMBL1201165

Cc1ccc(C)c(SCc2ccccc2C(O)C#N)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
TP53 P04637 2/20 0.38
L3MBTL1 Q9Y468 4/20 0.37
SMN1; SMN2 Q16637 5/20 0.36
GAA P10253 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 3/20 0.34
POLB P06746 4/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NOD2 Q9HC29 1/20 0.34
NOD1 Q9Y239 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.33
APOBEC3A P31941 1/20 0.33
ESR2 Q92731 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27808425 0.76 SMN1; SMN2 (0.41) LMNASMN1; SMN2TDP1ALDH1A1HPGD
SCHEMBL1200636 0.76 SMN1; SMN2 (0.41) LMNASMN1; SMN2TDP1ALDH1A1HPGD
SCHEMBL8594581 0.76 LMNA (0.38) LMNATP53L3MBTL1SMN1; SMN2GAA
SCHEMBL1200647 0.76 TSHR (0.43) L3MBTL1SMN1; SMN2GAATDP1ALDH1A1
SCHEMBL1199980 0.75 TSHR (0.41) L3MBTL1TDP1TSHR
SCHEMBL1200211 0.73 TSHR (0.39) SMN1; SMN2GAAKDM4EALDH1A1MEN1
SCHEMBL9667361 0.73 L3MBTL1 (0.42) LMNAL3MBTL1SMN1; SMN2TDP1ALDH1A1
SCHEMBL27940440 0.73 L3MBTL1 (0.42) LMNAL3MBTL1SMN1; SMN2TDP1ALDH1A1
SCHEMBL2555672 0.72 L3MBTL1 (0.42) LMNATP53L3MBTL1SMN1; SMN2TDP1
SCHEMBL21322250 0.71 L3MBTL1 (0.40) LMNATP53L3MBTL1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102007095-B Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL CO.,LTD. (JP) 2014-10-08 CN disclosed
US-8309753-B2 Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-13 US disclosed
CN-102007095-A Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL CO 2011-04-06 CN disclosed
US-20110034718-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2264005-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034718-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND CBR3, ACSL3, CCNL2 LMNA 441/4885TP53 3362/4885L3MBTL1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.